. 2021 Sep 8;10:100222. doi: 10.1016/j.lanepe.2021.100222

Table 4.

Impact of adherence to antithrombotic therapy on risk of stroke (efficacy) and bleeding (safety) in patients without chronic liver disease. Adjusted hazard ratios (HRs) are reported.

	A) Anticoagulant therapy
	Outcome = Ischaemic stroke
	HR	Lower CI	Upper CI	P value
Time not taking medication
All patients
< 1 week	1.00 (ref)
1 week to 1 month	0.993	0.919	1.072	0.85
1 to 3 months	1.049	0.958	1.149	0.31
3 to 6 months	1.216	1.164	1.270	< 0.0001
> 6 months	1.200	1.152	1.249	< 0.0001
CHA₂DS₂ VASc score 0-1
< 1 week	1.00 (ref)
1 week to 1 month	1.272	0.944	1.715	0.11
1 to 3 months	1.246	0.858	1.810	0.25
3 to 6 months	1.349	1.123	1.619	0.0013
> 6 months	1.367	1.152	1.622	< 0.0001
CHA₂DS₂ VASc score 2
< 1 week	1.00 (ref)
1 week to 1 month	0.998	0.785	1.269	0.99
1 to 3 months	1.091	0.810	1.469	0.57
3 to 6 months	1.435	1.254	1.642	< 0.0001
> 6 months	1.367	1.202	1.555	< 0.0001
CHA₂DS₂ VASc score 3-4
< 1 week	1.00 (ref)
1 week to 1 month	0.976	0.863	1.105	0.70
1 to 3 months	1.084	0.937	1.253	0.28
3 to 6 months	1.195	1.112	1.283	< 0.0001
> 6 months	1.266	1.185	1.354	< 0.0001
CHA₂DS₂ VASc score 5-9
< 1 week	1.00 (ref)
1 week to 1 month	1.011	0.900	1.137	0.85
1 to 3 months	1.020	0.891	1.168	0.77
3 to 6 months	1.154	1.082	1.231	< 0.0001
> 6 months	1.183	1.115	1.255	< 0.0001

	Outcome = Non-fatal bleeding
	HR	Lower CI	Upper CI	P value
	Without CLD
Per 10% increase in adherence (PDC)	1.079	1.017	1.144	0.012

	B) Antiplatelet therapy
	Outcome = Ischaemic stroke
	HR	Lower CI	Upper CI	P value
Time not taking medication
< 1 week	1.00 (ref)
1 week to 1 month	0.925	0.888	1.064	0.067
1 to 3 months	1.046	0.994	1.101	0.086
3 to 6 months	1.111	1.086	1.136	< 0.0001
> 6 months	1.315	1.287	1.343	< 0.0001

	Outcome = Non-fatal bleeding
	HR	Lower CI	Upper CI	P value
Per 10% increase in adherence (PDC)	1.183	1.144	1.224	< 0.0001